Akero Therapeutics (AKRO) Competitors

Genmab A/S (NASDAQ:GMAB) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Do analysts recommend GMAB or AKRO?

Genmab A/S presently has a consensus price target of $37.80, suggesting a potential upside of 71.97%. Akero Therapeutics has a consensus price target of $81.57, suggesting a potential upside of 67.77%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Akero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Akero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, GMAB or AKRO?

Genmab A/S has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.28, indicating that its stock price is 128% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of GMAB or AKRO?

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 7.1% of Akero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the media refer more to GMAB or AKRO?

In the previous week, Akero Therapeutics had 2 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Akero Therapeutics and 6 mentions for Genmab A/S. Akero Therapeutics' average media sentiment score of 1.36 beat Genmab A/S's score of 0.47 indicating that Akero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akero Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is GMAB or AKRO more profitable?

Genmab A/S has a net margin of 35.11% compared to Akero Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 18.08% beat Akero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	35.11%	18.08%	14.52%
Akero Therapeutics	N/A	-15.19%	-13.97%

Which has stronger earnings & valuation, GMAB or AKRO?

Genmab A/S has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	4.52	$1.14B	$1.76	12.49
Akero Therapeutics	N/A	N/A	-$252.06M	-$1.95	-24.93

Summary

Genmab A/S beats Akero Therapeutics on 11 of the 16 factors compared between the two stocks.